Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.33 |
| ▸ | HTR3A | P46098 | 3/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.33 |
| ▸ | HTR3B | O95264 | 2/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.30 |
| ▸ | MASP2 | O00187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL843039 | 0.83 | MEN1 (0.33) | JAK2BRD4CHRNA7HTR3AHTR3E | |
| SCHEMBL843840 | 0.79 | CHRNA7 (0.32) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL843470 | 0.79 | MASP2 (0.39) | JAK2BRD4CHRNA7HTR3AHTR3E | |
| SCHEMBL843678 | 0.79 | CHRNA7 (0.53) | JAK2BRD4CHRNA7HTR3AHTR3E | |
| SCHEMBL843572 | 0.79 | CHRNA7 (0.52) | JAK2BRD4CHRNA7HTR3AHTR3E | |
| SCHEMBL6479979 | 0.77 | CHRNA7 (0.57) | JAK2BRD4CHRNA7HTR3AHTR3E | |
| SCHEMBL6099172 | 0.76 | SSTR3 (0.34) | BRD4CHRNB4CHRNA3SSTR3CNR2 | |
| SCHEMBL6100152 | 0.76 | SSTR3 (0.39) | BRD4CHRNB4CHRNA3NPC1RAB9A | |
| SCHEMBL6100158 | 0.75 | PRKAA2 (0.34) | CHRNB4CHRNA3SSTR3CNR2 | |
| SCHEMBL6099424 | 0.75 | SSTR3 (0.38) | CHRNB4CHRNA3SSTR3CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432707-B1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN CO LLC (US) | 2012-03-28 | — | — | EP | claimed |
| US-20050234092-A1 | Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease | PFIZER INC | 2005-10-20 | — | — | US | claimed |
| EP-1432707-A1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-06-30 | — | — | EP | claimed |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-08-14 | — | — | US | claimed |
| WO-2003029252-A1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-10 | — | — | WO | claimed |
| EP-1432707-B1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN CO LLC (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20050234092-A1 | Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| US-20050222196-A1 | Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease | PFIZER INC. | 2005-10-06 | — | — | US | disclosed |
| US-6911543-B2 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PFIZER INC. (US) | 2005-06-28 | — | — | US | disclosed |
| EP-1432707-A1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-08-14 | — | — | US | disclosed |
| WO-2003029252-A1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234092-A1 | Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease | UGT2B7, CYP3A7, UGT1A7 | JAK2 2174/4885BRD4 1326/4885CHRNA7 5/4885 |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | MALT1, TPMT, ABCB1 | JAK2 1258/4885BRD4 1468/4885CHRNA7 1401/4885 |
| US-20050222196-A1 | Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease | UGT2B7, CYP3A7, UGT1A7 | JAK2 2174/4885BRD4 1326/4885CHRNA7 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.